Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1783/147118910791749399 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Male Breast Cancer in Portugal: A Descriptive Analysis of a 20-Year Cohort.
Eur J Breast Health
March 2025
Department of Medical Oncology, Academic Clinical Center, São José Local Health Unit, Lisbon, Portugal.
Objective: Male breast cancer (MBC) is a rare malignancy, representing less than 1% of all breast cancer cases. Despite the rising incidence, MBC research remains limited, with most data extrapolated from female breast cancer (FBC). This study evaluated the clinicopathological features, treatment strategies, and survival outcomes of MBC patients in Portugal over two decades.
View Article and Find Full Text PDFNongenomic Progesterone Receptors Mediated Bull Sperm Capacitation and Acrosome Reaction Are cAMP-PKA-Calcium Channel Dependent.
Reprod Domest Anim
March 2025
College of Veterinary Science and Animal Husbandry, UP Pandit Deen Dayal Upadhaya Pashuchikitsa Vigyan Vishwavidyalaya Evam Go-Anusandhan Sansthan, Mathura, India.
Progesterone (P4) secreted from the cumulus cells mediates nongenomic signalling in sperm cells and induces capacitation and acrosome reaction in the oviduct. The induction of these events in bull spermatozoa is not fully understood. Recently, we reported the presence of membrane nongenomic P4 receptors in bull spermatozoa and the involvement of P4-nongenomic signalling through the involvement of complex signalling pathways with cannabinoid receptors in the regulation of bull sperm capacitation and acrosome reaction.
View Article and Find Full Text PDFIntroduction: Breast cancer is among the most prevalent cancers in women globally, with patients' survival adversely impacted by Ki67 expression and triple-negative phenotypes. In this study, we examined the relationship between HER2/neu, triple-negative, and Ki67 phenotypes and tumor aggressiveness along with the survival of breast cancer patients from India.
Materials And Methods: A retrospective cohort study was performed using hospital-based data from a tertiary care center spanning January 2013 to August 2023.
Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review.
Int J Mol Sci
February 2025
SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain.
Breast cancer is the most clinically relevant pathology of the mammary gland and is currently the most diagnosed malignant disease among women worldwide. In breast cancer prevention, it is important to consider that the risk of developing the disease is not the same for the entire population. This pathology presents heterogeneous clinical manifestations and the most common classification is related to the following hormonal receptors: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and triple-negative (TNBC).
View Article and Find Full Text PDFRadiogenomic Landscape of Metastatic Endocrine-Positive Breast Cancer Resistant to Aromatase Inhibitors.
Cancers (Basel)
February 2025
SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield 0028, South Africa.
Breast cancer poses a significant global health challenge and includes various subtypes, such as endocrine-positive, HER2-positive, and triple-negative. Endocrine-positive breast cancer, characterized by estrogen and progesterone receptors, is commonly treated with aromatase inhibitors. However, resistance to these inhibitors can hinder patient outcomes due to genetic and epigenetic alterations, mutations in the estrogen receptor 1 gene, and changes in signaling pathways.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!